Atlas Trials

Orelabrutinib Combined With Induction Therapy Followed by Sequential Monotherapy Maintenance in MCD Subtype Diffuse Large B-cell Lymphoma

Clinical trial NCT07677813 · NOT_YET_RECRUITING

Trial details

NCT number
NCT07677813
Sponsor
Ou Bai, MD/PHD
Status
NOT_YET_RECRUITING
Phase
Phase 2
Study type
INTERVENTIONAL
DLBCL - Diffuse Large B Cell Lymphoma
Start date
2026-06-16
Primary completion
2029-12-31
Enrollment
66

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.